News brief
On September 3, 2026, Beijing-based AIPher, an AI-native drug developer, raised RMB 100 million in an Angel round led by Xianghe Capital. Gao Bowen serves as CEO, Lan Yanyan as chief scientist and Zhang Yaqin as chief scientific advisor.
Connected profiles
Sources · 1Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
- www.cnr.cn ↗Published Sep 3, 2026
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年9月3日，据央广网报道，北京AI Native新药研发商艾斐智药完成亿元人民币天使轮融资，由襄禾资本领投。公司由高博文任CEO、兰艳艳任首席科学家、张亚勤任首席科学顾问。